

The effects of door-to-balloon time on clinical outcomes in patients with ST-elevation myocardial infarction aged 75 years or older, 75 to 84 years old, or 85 years old or older.

DR TANMAY KUMAR DAS

SENIOR CONSULTANT CARDIOLOGY. ASWINI HOSPITAL BHUBANESWAR.

Abstract:

Background: Within the first ninety minutes, sometimes called the door-to-balloon time (DTBT), medical professionals strongly recommend that patients with ST-elevation myocardial infarction (STEMI) get mechanical reperfusion. **Aim:** This study set out to examine, within a group of patients aged 75 and above, the intricate connection between the time elapsed between the door and the balloon and the clinical outcomes. After that, we subdivided this cohort further into those aged 75–84 and those aged 85 and higher. **Materials and methods:** Following the acceptance of consent from the Institutional Ethics Committee, this study's first point of departure was determined. The investigation was conducted at the Care Hospital in Bhubaneswar, which was the healthcare facility's site. **Results:** Patients as young as 75 and younger were included in the younger group. People deemed elderly were those between the ages of 75 and 84.

On the other hand, those who were 85 were considered among the demographic of elderly citizens considered exceedingly old. This study aimed to reduce the number of major adverse cardiovascular events (MACE) and death rates after one year. One hundred eighteen of the patients were eighty-five years old, and thirty-four were in the age range of seventy-five to eighty-four years old. Participants in this study had an average age of 60.1 years, making it a relatively young group. We discovered a tendency in the senior population (p -for-trend = 0.10) and a substantial drop in DTBT with time in both younger and older persons (p -for-trend = 0.02, 0.05).

Similarly, a pattern appeared among the somewhat younger patients. A greater mortality rate (4.1% compared to 11.2% vs 31%; $p < 0.05$) was seen among those who were highly elderly all during the 12 months investigated. Additionally, it was shown that they had a higher probability of developing major adverse cardiovascular events (MACE) (11.7% vs 21.8% versus 34.6%; $p < 0.05$). A more favourable outcome was linked to DTBT for 90 minutes. While it did reduce mortality at 12 months (OR0.89, 95% CI0.61–1.45), it was not a reliable predictor of severe adverse cardiovascular events (OR0.91, 95% CI0.71–1.21). We arrived at this result using a univariate analysis. **Conclusion:** A 90-minute DTBT was not proven to be an independent predictor of outcomes at one year, even though DTBT improved in patients aged 75 and 75–84 over ten years compared to the duration of the experiment. Therefore, it is not always the case that less favourable clinical outcomes are more favourable when deciding whether patients above 85 are suitable candidates for invasive therapy.

Keywords: ST-elevation myocardial infarction, door-to-balloon time, clinical outcome, invasive care, major adverse cardiovascular events.

Introduction:

Research conducted in the field of cardiovascular medicine has seen a remarkable surge in recent years [1-3]. This research's primary focus is an ST-elevation myocardial infarction (STEMI) management strategy. The "door-to-balloon time" is currently considered an essential parameter for treating acute coronary syndrome. It is also considered to be one of the most significant factors that have a direct role in determining the outcomes for patients [4]. With the difficulties that come with becoming older, which make it difficult to intervene promptly and effectively, particular attention has been given to the elderly. [5] This is due to the hurdles that come with getting older.

It is of the highest significance to enhance treatment techniques by knowing the unique impact of early reperfusion therapy on patients of various age groups [1]. This is because the number of elderly people is constantly growing, so it is necessary to improve treatment methods. Due to the numerous studies conducted on the relationship between door-to-balloon time and STEMI outcomes [2], it is crucial to comprehensively evaluate the senior population, especially stratifying participants based on their age. This study aims to investigate the relationship between clinical outcomes, door-to-balloon time, and age. By doing so, we can provide evidence-based recommendations and implement tailored solutions [6-8]. This research aimed to improve the management of STEMI in the elderly population as its primary objective. This new information can potentially improve patient treatment, and a shift in clinical practices and a decrease in cardiovascular disease affect this group of individuals at risk [7].

This study set out to examine, within a group of patients aged 75 and above, the intricate connection between the time elapsed between the door and the balloon and the clinical outcomes. Those in the 75–84 age bracket and those 85 and higher were the following subcategories formed from this larger group.

Materials & methods:

After obtaining consent from the Institutional Ethics Committee, the study project was formally launched when completed. The investigation was conducted at the Care Hospital in Bhubaneswar, the study's central site. Prospective collection of demographics, clinical, procedural, and in-hospital outcome data was carried out using case report forms. These forms were utilized following predefined criteria for each area respectively. The outcomes that occurred inside the hospital were recorded at the moment of death or discharge. The thirty-day and twelve-month follow-ups were documented using a mix of reviewing the patient's medical records and performing a telephone interview using a template questionnaire. Another thing that we did was figure out the follow-up rates for the first thirty days and the first year overall. Including the use of "opt-out" permission, the medical information group register (MIG) has been given the go-ahead by the ethical committees of all the hospitals participating in the study.

It is assumed that permission has been granted until the patient "opts out" after being provided with a "Patient Information Sheet." This will continue so long as the patient does not express any

disagreement. When this occurs, the personnel does not consider the patient's desire to exit the study. Patients with ST-elevation myocardial infarction who presented within the last 12 hours were the subjects of this study. When an electrocardiogram (ECG) revealed an ST-segment elevation or a new or suspected new left bundle branch block that lasted for twenty minutes, a diagnosis of stress-induced myocardial infarction (STEMI) was made. This was essential since the evidence had been present for twenty minutes. When an electrocardiogram (ECG) reveals a prolonged ST-segment elevation at the J-point in two consecutive leads (0.2 mV in males and 0.15 mV in women in leads V2–V3, or 0.1 mV in all other leads), this is referred to as an ST-elevation. This elevation is referred to as a constant. Either electrical line has the potential to experience ST-elevation. There is a possibility that ST elevation might take place in either direction. An additional need is the presence of symptoms of myocardial ischemia or a clinical manifestation that meets these requirements. In addition, evidence is required that the blood levels of cardiac biomarkers at the relevant institution are higher than the upper normal limits.

It was not possible for patients to participate in the trial if they had undergone thrombolysis, suffered cardiac arrest outside of a hospital, or came within the first twelve hours after the onset of symptoms. The researchers investigated whether major adverse events (MACEs) and patient death after a year were the most significant results during this trial. The phrase "myocardial infarction and mortality" incorporates three different concerns. Death, myocardial infarction, and revascularization of the target vessel are not uncommon. The evaluation of MACE and death after 30 days was a secondary objective. One of the safety outcomes that was investigated in this study was hospital haemorrhage. Ischemic heart disease can be identified by the presence of three times the upper limit of normal for creatine kinase or creatine kinase-MB, a considerable shift in the ST segment, new Q waves in two adjacent electrocardiographic leads, or a new left branch bundle block pattern with new clinical symptoms. All of these indicators point to the patient having ischemic heart disease. All of these traits were formerly thought to be indicators of ischemic heart disease before their discovery. According to the criteria, there was bleeding that necessitated a transfusion, and there was a prolonged hospital stay that was accompanied by a decline in haemoglobin that was more significant than three gauges per deciliter. A hospital had bleeding that happened within the facility itself.

Statistical analysis:

To portray categorical data, numerical values or percentages were used as the representational format. The mean plus or minus the standard deviation was applied simultaneously when it came to continuous variables. The Chi-square test and Fisher's exact test were the two methods that researchers used when comparing different categories. Both kinds of testing were used. To analyze the continuous variables, Kruskal-Wallis's equality-of-populations rank test was applied as the technique of analysis.

Results:

The younger cohort of participants includes people as young as 75 years old. This group of people was comprised of individuals. Patients who were 85 years old were thought to be very elderly patients. Individuals who were between the ages of 75 and 84 years old were believed to be elderly,

while those who were between those two age ranges were considered to be elderly. The main goals of this study were to determine the annual mortality rate and the prevalence of cardiovascular disease (MACE). The average age of the patients was 60.1 years, and 68 were 75 years old. The total number of patients was 75. To add insult to injury, 18 patients were 85 years old, while 34 were between 75 and 84. Although DTBT decreased somewhat among the extremely old ($p = 0.10$), it decreased significantly with time across patients in the younger and older age groups ($p = 0.02, 0.05, \text{ and } 0.02$, respectively). This occurrence was seen in DTBT patients of varying ages. The death rate was much more remarkable for the highly elderly patients when compared with other age groups. After a period of twelve months, the mortality rate for these patients was 4.1%, which was significantly higher than the rates for the other age groups, which were 11.2% and 301%, respectively ($p < 0.05$). It is also worth noting that their rate of MACE (11.7%) was higher than the rates of the other age groups (21.8%) and the general population (34.6%). A result that seems to be statistically significant ($p < 0.05$) has been seen. However, the results of the univariate analysis showed that neither improved 12-month mortality (odds ratio [OR] 0.89, 95% confidence interval [CI] 0.61-1.45) nor significant adverse cardiovascular events (MACE) (OR 0.91, 95% CI 0.71-1.21) could be independently predicted by DTBT over a period of ninety minutes. This was the conclusion reached by the researchers.

Discussion:

Patients younger than 75 years old or between the ages of 75 and 84 and undergoing DTBT noticed a significant improvement in their quality of life. This was seen since these patients were receiving the treatment. On the other hand, patients who were older than 85 years showed a trend toward improvement, in contrast to younger persons. Second, patients who were old or elderly had much bigger short- and medium-term adverse outcomes, even after taking into account the fact that there were differences in the characteristics of the patients at the beginning of the experiment. This was the case even though the trial was conducted with different individuals. This was shown to be the case after analyzing the data obtained from the experiment. There was no change in the fact that this was constant despite a larger sample size being used in the investigation. The last finding was that there was no independent link discovered between DTBTs that lasted less than 90 minutes and MACE or death one year later. This was the conclusion reached by their researchers. The researchers came to this realization as a result of their investigation. Those extremely elderly or older had a lower likelihood of receiving effective medicines, such as drug-eluting stents, glycoprotein IIb/IIIa inhibitors, and adequate secondary preventative medications. This was the case since these therapeutic options were more challenging to obtain. Therefore, the likelihood of accessing these therapies was diminished due to this change. The fact that these people were in their twilight years is the most critical factor to consider while attempting to comprehend this occurrence. In conclusion, this was the last item to be communicated to the audience. The guidelines that have been issued [7,8] state that the therapy of choice for patients who come with ST-elevation myocardial infarction should be rapid mechanical reperfusion. This is the recommended course of treatment. It is recommended that older patients have a technique known as percutaneous coronary intervention (PCI), considered the gold standard, prior to thrombolysis [9]. On the other hand, our research and earlier studies have shown that older patients, in contrast to younger patients (those under 75 years old), have a much more significant burden of medical comorbidities [4,5]. This is because older patients have to deal with more medical conditions. In

addition, the percentage of people in our sample population with cognitive and functional problems is much more significant than the average [8]. In addition to the information just presented, the following is additional information. It would appear that elderly patients who have been diagnosed with ST-elevation myocardial infarction (STEMI) have lower rates of perfusion. This is because it becomes more difficult to continuously do primary percutaneous coronary intervention (PCI) in these individuals [9–11]. Individuals who had undergone their initial percutaneous coronary intervention (PCI) had a much higher rate of successful treatments as compared to patients who were either extraordinarily elderly or very young. When comparing the success rates recorded in the Bremen Registry to those of studies done on octogenarians and nonagenarians, the Bremen Registry found that the success rates were 88.5% (75-84 years) and 83.2% (≥ 85 years) [11–13]. Compared to the success rates published in the Bremen Registry records, this one is significantly higher. Even if the treatment has a high success rate overall, it is essential to keep in mind that the death rate for persons aged 85 and older remains much higher after 30 days and after 12 months. This is something that should be taken into consideration. This continues to be the case even after because there are variations in the properties of the baseline. Some data suggests that invasive therapy may be an independent predictor of long-term survival [14], although there is a lack of consensus among many persons about whether or not all patients of this age should have access to invasive therapy. This is because many people are arguing whether or not it should be offered. This is the reason why this is the case.

There is an effort to achieve timely reperfusion on the theory that it may reduce myocardial necrosis and infarct size by reducing the duration of ischemia via rapid reperfusion [11]. Extensive observational studies [15,16] highlight the correlation between shorter DTBT and improved results. Research like this lends support to the idea that this might be true. The current recommendation is that patients in class I complete a DTBT of ninety minutes or fewer, in line with internationally accepted norms. Contrarily, not all studies have shown a correlation between a decrease in DTBT and concurrent mortality reduction [5].

Further research on this is needed. Research conducted in the US over four years indicated that DTBT significantly improved performance [17]. It was concluded that this enhancement had taken place. Despite this tendency, outcomes were not improved during hospitalization or after 30 days for the overall cohort or the subset of patients older than 75 years. Regarding theoretical importance, the two most pressing issues are the early reperfusion of older patients and the avoidance of cardiac necrosis. People's physiologic reserves decrease with age, making them more susceptible to health problems [18]. Patients under 65 are underrepresented in the drug-eluting stent and glycoprotein IIb/IIIa inhibitor populations. However, both medications are strong indicators of better survival. This is true regardless of whether these drugs prolong life expectancy.

Conclusion:

Even in this day and age, the amount of time that elapses between the arrival of a patient at the hospital, the diagnosis of sudden cardiac arrest (STEMI), and the activation of the catheterization lab (also known as the "door-to-activation time") are still highly variable. It constitutes a significant component in determining the overall duration of the "door-to-balloon" procedure. There was a direct correlation between reducing the time from the door to the balloon to less than ninety

minutes and preventing the triage and diagnostic phase, also called the door-to-activation period, from lasting longer than twenty minutes. Considering the statistics presented here, it appears that a reduction in this time might be an effective quality measure. Currently, the catheterization team does not significantly impact the variances that occur in the timing of the door-to-balloon transition. This is because the bulk of these eras are characterized by the events that have occurred during historical eras. This is the reason why this is the case. There is a possibility that the delay in timely reperfusion with PCI is not the primary cause for the lack of attention devoted to therapies that are purely focused on shortening door-to-balloon timeframes that are commenced after a diagnosis of STEMI. This is something that needs to be investigated further at this point. For this particular matter, further research needs to be conducted.

Conflict of interest:

The authors declare that they have no conflict of interest.

References:

1. Brush Jr JE, Chaudhry SI, Dreyer RP, D'Onofrio G, Greene EJ, Hajduk AM, Lu Y, Krumholz HM. Sex Differences in Symptom Complexity and Door-to-Balloon Time in Patients With ST-Elevation Myocardial Infarction. *The American Journal of Cardiology*. 2023 Jun 15;197:101-7.
2. Hsiao YT, Hung JF, Zhang SQ, Yeh YN, Tsai MJ. The Impact of Emergency Department Arrival Time on Door-to-Balloon Time in Patients with ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary Intervention. *Journal of Clinical Medicine*. 2023 Mar 20;12(6):2392.
3. Congost GB, Momblan MA, Bernal JV, López AM, Gabalda JR, Garcia-Picart J, Campmany MP, Brugaletta S. Association of sex and age and delay predictors on the time of primary angioplasty activation for myocardial infarction patients in an emergency department. *Heart & Lung*. 2023 Mar 1;58:6-12.
4. Jamalian M, Roohafza H, Soleimani A, Massoumi G, Mirmohammadsadeghi A, Dorostkar N, Yazdekhashti S, Azarm M, Sadeghi M. Predictors of mortality for patients with ST-elevation myocardial infarction after 2-year follow-up: A ST-elevation myocardial infarction cohort in Isfahan study. *Advanced Biomedical Research*. 2022;11.
5. Mohsenizadeh SA, Alidoosti M, Jalali A, Tofighi S, Salarifar M, Poorhosseini H, Jenab Y, Ahmadian T. Comparison of angiographic and clinical outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction between patients with and without concomitant COVID-19 infection. *Critical Pathways in Cardiology*. 2022 Sep 1;21(3):141-6.
6. Ahsan MJ, Ahmad S, Latif A, Lateef N, Ahsan MZ, Abusnina W, Nathan S, Altin SE, Kolte DS, Messenger JC, Tannenbaum M. Transradial versus transfemoral approach for percutaneous coronary intervention in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a systematic review and meta-analysis. *European Heart Journal-Quality of Care and Clinical Outcomes*. 2022 Nov;8(6):640-50.
7. Hassani NS, Mozafarybazargany M, Pirdehghan R, Sepahvandi R, Khodaprast Z, Karimi F, Rahimi F, Zakani A, Mardi P, Kamipoor Z, Dorri M. The outcome of ST-elevation

- myocardial infarction by sex: a retrospective cohort study. *Future Cardiology*. 2023 Jan;19(1):19-27.
8. Dang D, Dowling C, Zaman S, Cameron J, Kuhn L. Predictors of radial to femoral artery crossover during primary percutaneous coronary intervention in ST-elevation myocardial infarction: A systematic review and meta-analysis. *Australian Critical Care*. 2022 Dec 7.
 9. Bawamia B, Brown A, Spyridopoulos I, Bagnall A, Edwards R, Purcell I, Egred M, Zaman A, Alkhalil M. Very early discharge after primary percutaneous coronary intervention for ST-elevation myocardial infarction: mortality outcomes at six months. *Cardiovascular Revascularization Medicine*. 2023 Jan 1;46:12-8.
 10. Moriwaki K, Kurita T, Hirota Y, Ito H, Ishise T, Fujimoto N, Masuda J, Ishikura K, Tanigawa T, Yamada N, Kawasaki A. Prognostic Impact of Prehospital Simple Risk Index in Patients With ST-Elevation Myocardial Infarction. *Circulation Journal*. 2023 Apr 25;87(5):629-39.
 11. Fach A, Bünger S, Zabrocki R, Schmucker J, Conradi P, Garstka D, Fiehn E, Hambrecht R, Weinberg H. Comparison of outcomes of patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention analyzed by age groups (< 75, 75 to 85, and > 85 Years);(Results from the Bremen STEMI Registry). *The American journal of cardiology*. 2015 Dec 15;116(12):1802-9.
 12. Velders MA, James SK, Libungan B, Sarno G, Fröbert O, Carlsson J, Schaliij MJ, Albertsson P, Lagerqvist B. Prognosis of elderly patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention in 2001 to 2011: A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) registry. *American Heart Journal*. 2014 May 1;167(5):666-73.
 13. Hafiz AM, Jan MF, Mori N, Gupta A, Bajwa T, Allaqaband S. Contemporary Clinical Outcomes of Primary Percutaneous Coronary Intervention in Elderly versus Younger Patients Presenting with Acute ST-Segment Elevation Myocardial Infarction. *Journal of Interventional Cardiology*. 2011 Aug;24(4):357-65.
 14. Waziri H, Jørgensen E, Kelbæk H, Stagmo M, Pedersen F, Lagerqvist B, James S, Køber L, Wachtell K. Short and long-term survival after primary percutaneous coronary intervention in young patients with ST-elevation myocardial infarction. *International Journal of Cardiology*. 2016 Jan 15;203:697-701.
 15. Berger PB, Ellis SG, Holmes Jr DR, Granger CB, Criger DA, Betriu A, Topol EJ, Califf RM. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. *Circulation*. 1999 Jul 6;100(1):14-20.
 16. Rathore SS, Curtis JP, Nallamothu BK, Wang Y, Foody JM, Kosiborod M, Masoudi FA, Havranek EP, Krumholz HM. Association of door-to-balloon time and mortality in patients \geq 65 years with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *The American journal of cardiology*. 2009 Nov 1;104(9):1198-203.
 17. Menees DS, Peterson ED, Wang Y, Curtis JP, Messenger JC, Rumsfeld JS, Gurm HS. Door-to-balloon time and mortality among patients undergoing primary PCI. *New England Journal of Medicine*. 2013 Sep 5;369(10):901-9.

18. Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM. Acute coronary care in the elderly, part II: ST-segment–elevation myocardial infarction: A scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: In collaboration with the Society of Geriatric Cardiology. *Circulation*. 2007 May 15;115(19):2570-89.